Docebo
DCBO
27.82
-1.57
-5.34%
Docebo
US · DCBO
#3632 by market cap
27.82
-1.57
-5.34%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.62, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +11.87% YoY
Margins
- Gross margin
- 80.28%
- Operating margin
- 10.09%
- Net margin
- 15.46%
Key ratios & quality
- PEG ratioi
- 0.28
- Altman Z-Scorei
- 3.62
PEG uses trailing P/E against the 3-year net income growth rate (74.84%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 27.07M | 41.44M | 62.92M | 104.24M | 142.91M | 180.84M | 216.93M | 242.69M |
| Gross profit | 21.42M | 33.08M | 51.38M | 83.46M | 114.73M | 146.34M | 175.64M | 194.84M |
| Selling & admin expenses | 22.82M | 31.84M | 42.64M | 74.05M | 94.55M | 107.04M | 109.44M | 117.05M |
| Research & development | 6.61M | 9.44M | 13.38M | 20.36M | 24.78M | 35.48M | 43.91M | 50.12M |
| Operating profit | -8.18M | -8.89M | -5.85M | -12.98M | -6.93M | 680.00K | 18.91M | 24.48M |
| Pretax profit | -11.65M | -11.31M | -7.68M | -13.43M | 7.78M | 4.85M | 23.71M | 24.45M |
| Tax | 0 | 609.00K | 336.00K | 172.00K | 764.00K | 2.01M | -3.02M | -13.07M |
| Net profit | -11.65M | -11.91M | -8.02M | -13.60M | 7.02M | 2.84M | 26.74M | 37.51M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Diluted EPS | -0.40 | -0.49 | -0.28 | -0.41 | 0.21 | 0.08 | 0.86 | 1.28 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | 60.73M | 61.62M | 63.04M | 65.62M | 68.65M | 70.33M |
| Gross profit | 49.15M | 49.49M | 50.30M | 51.27M | 54.53M | 55.76M |
| Selling & admin expenses | 30.52M | 28.70M | 27.96M | 33.93M | 34.49M | 30.27M |
| Research & development | 12.70M | 11.91M | 12.11M | 15.46M | 12.99M | 11.72M |
| Operating profit | 5.08M | 8.14M | 9.42M | -39.00K | 4.86M | 11.38M |
| Pretax profit | 4.68M | 8.25M | 9.16M | -1.90M | 1.50M | 9.89M |
| Tax | 1.61M | 2.14M | -17.69M | -284.00K | -761.00K | 463.00K |
| Net profit | 3.08M | 6.11M | 26.85M | -1.62M | 2.26M | 9.43M |
| Basic EPS | 0 | 0 | 1 | 0 | 0 | 0 |
| Diluted EPS | 0.10 | 0.21 | 0.91 | -0.06 | 0.08 | 0.37 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 11.64M | 58.94M | 239.73M | 251.59M | 263.59M | 127.15M | 154.24M | 151.52M |
| Cash & ST investments | 3.76M | 46.37M | 219.76M | 215.42M | 216.47M | 72.03M | 92.58M | 74.04M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 13.30M | 63.86M | 254.24M | 268.22M | 283.67M | 158.38M | 190.71M | 206.65M |
| Total current liabilities | 24.89M | 28.54M | 45.73M | 69.27M | 84.36M | 100.65M | 128.60M | 123.80M |
| Short-term debt | 5.36M | 955.00K | 1.28M | 1.31M | 1.37M | 1.47M | 1.34M | 621.00K |
| Long-term debt | 4.02M | 16.00K | -- | -- | -- | -- | -- | -- |
| Total liabilities | 30,076,000.00 | 32,479,000.00 | 53,938,000.00 | 77,566,000.00 | 91,458,000.00 | 107,654,000.00 | 132,952,000.00 | 132,556,000.00 |
| Total equity | -16.78M | 31.38M | 200.31M | 190.66M | 192.21M | 50.72M | 57.76M | 74.09M |
| Retained earnings | -48.32M | -60.27M | -68.29M | -81.89M | -74.87M | -204.79M | -205.37M | -184.04M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | 136.03M | 137.32M | 151.52M | 137.14M | 120.36M | 120.49M |
| Cash & ST investments | 64.58M | 66.13M | 74.04M | 63.19M | 45.72M | 42.49M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 171.23M | 173.23M | 206.65M | 253.55M | 242.72M | 241.71M |
| Total current liabilities | 131.09M | 121.07M | 123.80M | 161.11M | 145.51M | 150.25M |
| Short-term debt | 1.01M | 864.00K | 621.00K | 1.41M | 1.94M | 1.84M |
| Long-term debt | -- | -- | -- | 79.09M | 87.95M | 88.22M |
| Total liabilities | 136,548,000.00 | 127,992,000.00 | 132,556,000.00 | 254,166,000.00 | 243,022,000.00 | 247,389,000.00 |
| Total equity | 34.68M | 45.24M | 74.09M | -616.00K | -306.00K | -5.68M |
| Retained earnings | -219.78M | -210.56M | -184.04M | -233.18M | -230.47M | -236.36M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -2.30M | -4.58M | 4.79M | -3.25M | 2.29M | 15.96M | 29.25M | 28.17M |
| Depreciation & amortization | 169.00K | 693.00K | 1.21M | 2.02M | 2.33M | 3.14M | 3.38M | 3.19M |
| Free cash flow | -2.71M | -4.95M | 3.71M | -4.40M | 1.21M | 15.33M | 28.00M | 27.19M |
| Dividends paid | 0 | 0 | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 56.26M | 184.63M | -- | 0 | -159.45M | -11.02M | -47.05M |
| Ending cash balance | 3.76M | 46.28M | 219.66M | 215.32M | 216.29M | 71.95M | 92.54M | 74.04M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | 6.24M | 5.29M | 8.69M | 24.81M | -3.07M | 4.15M |
| Depreciation & amortization | 847.00K | 743.00K | 798.00K | 1.92M | 2.20M | 2.40M |
| Free cash flow | 5.96M | 5.07M | 8.52M | 24.70M | -3.25M | 3.89M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -34.21M | -3.40M | -40.00K | -63.11M | -16.31M | -2.84M |
| Ending cash balance | 64.58M | 66.13M | 74.04M | 63.19M | 45.72M | 42.49M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -163.15 | -6.60 | -6.95 | 3.67 | 2.34 | 49.29 | 56.90 |
| ROA %i | -98.86 | -30.88 | -4.81 | -5.20 | 2.54 | 1.28 | 15.32 | 18.88 |
| ROIC %i | -- | -82.82 | -6.32 | -6.79 | 1.96 | -2.28 | 44.41 | 53.34 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -34.20 | 8.28 | 21.05 |
| EBIT margin %i | -40.93 | -25.46 | -10.94 | -12.41 | 5.71 | 2.84 | 11.02 | 10.13 |
| FCF / sales %i | -- | -- | 5.90 | -- | 0.84 | 8.48 | 12.91 | 11.20 |
| Current ratioi | 0.47 | 2.07 | 5.24 | 3.63 | 3.12 | 1.26 | 1.20 | 1.22 |
| Quick ratioi | 0.40 | 1.98 | 5.15 | 3.51 | 3.02 | 1.14 | 1.07 | 1.05 |
| Debt / assetsi | 70.51 | 5.40 | 1.50 | 1.49 | 1.08 | 1.33 | 0.78 | 1.24 |
| LT debt / equityi | -- | 7.95 | 1.27 | 1.41 | 0.88 | 1.26 | 0.27 | 2.62 |
| Interest coveragei | -19.51 | -14.01 | -15.86 | -26.18 | 21.70 | 17.37 | 129.18 | 168.43 |
| Revenue CAGR (3Y) %i | -- | 61.43 | 54.30 | 56.73 | 51.08 | 42.18 | 27.67 | 19.31 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | 74.84 |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | 60.46 | -- | 182.43 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | 55.53 | 49.99 | 56.90 | 132.85 | 195.48 | 186.65 |
| ROA %i | 12.42 | 12.99 | 18.88 | 15.26 | 16.23 | 17.79 |
| ROIC %i | 48.51 | 43.19 | 53.34 | 49.75 | 52.75 | 56.52 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 9.07 | 10.06 | 10.13 | 8.34 | 7.26 | 8.13 |
| FCF / sales %i | 11.67 | 11.88 | 11.20 | 17.63 | 13.53 | 12.65 |
| Current ratioi | 1.04 | 1.13 | 1.22 | 0.85 | 0.83 | 0.80 |
| Quick ratioi | 0.87 | 0.93 | 1.05 | 0.72 | 0.69 | 0.67 |
| Debt / assetsi | 0.80 | 1.68 | 1.24 | 33.05 | 38.63 | 38.70 |
| LT debt / equityi | 1.05 | 4.51 | 2.62 | -- | -- | -- |
| Interest coveragei | 146.26 | 168.92 | 168.43 | 28.39 | 10.42 | 7.01 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Docebo discussion 0 comments